Healthcare · NIFTY 500
Alkem Laboratories Limited
₹5,136.00 +22.00 (+0.43%) Updated 16 Nov, 8:14 pm IST
Today
- Open
- ₹5,115.00
- Prev close
- ₹5,114.00
- Day high
- ₹5,186.50
- Day low
- ₹5,096.00
- Volume
- 72.8 K
- Value traded
- ₹37.41 Cr
- Upper circuit
- ₹5,282.00
- Lower circuit
- ₹4,975.00
- 52W high
- ₹5,933.50
- 52W low
- ₹4,811.00
- 1 month
- -0.13%
- 6 months
- -6.47%
Ratios
Key numbers
Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.
Quarterly results
Results for each quarter
Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.
Revenue and net profit
Revenue · QoQ (vs last quarter)
Revenue · YoY (vs a year ago)
Net profit · QoQ (vs last quarter)
Net profit · YoY (vs a year ago)
EPS (₹) · YoY (vs a year ago)
| ₹ Cr | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,324 | 2,936 | 3,032 | 3,415 | 3,374 | 3,144 | 3,371 | 4,001 | 3,737 | 3,603 | 3,740 | 4,552 |
| Other income | 93.6 | 88.2 | 120 | 134 | 93.0 | 146 | 136 | 104 | 143 | 200 | 153 | 134 |
| Total income | 3,418 | 3,024 | 3,152 | 3,549 | 3,467 | 3,290 | 3,508 | 4,105 | 3,880 | 3,803 | 3,893 | 4,686 |
| Raw material | 839 | 799 | 837 | 902 | 924 | 777 | 827 | 906 | 938 | 895 | 910 | 1,083 |
| Purchases | 461 | 381 | 383 | 354 | 397 | 380 | 397 | 472 | 328 | 498 | 366 | 469 |
| Employee cost | 572 | 506 | 602 | 610 | 625 | 616 | 693 | 710 | 722 | 712 | 809 | 897 |
| Other expenses | 740 | 921 | 745 | 847 | 786 | 857 | 768 | 969 | 915 | 1,126 | 964 | 1,136 |
| Total expenses | 2,711 | 2,644 | 2,533 | 2,769 | 2,736 | 2,893 | 2,750 | 3,209 | 3,046 | 3,246 | 3,121 | 3,722 |
| Operating profit | 656 | 389 | 609 | 753 | 759 | 391 | 752 | 921 | 775 | 382 | 766 | 1,060 |
| OPM % | 19.7% | 13.3% | 20.1% | 22.0% | 22.5% | 12.4% | 22.3% | 23.0% | 20.7% | 10.6% | 20.5% | 23.3% |
| Finance cost | 25.5 | 26.9 | 29.1 | 28.1 | 36.0 | 28.4 | 29.8 | 35.0 | 42.1 | 53.9 | 46.6 | 57.7 |
| Depreciation | 69.6 | 83.4 | 80.5 | 78.9 | 85.3 | 112 | 87.7 | 93.6 | 95.0 | 106 | 100 | 137 |
| Exceptional items | -51.3 | -12.5 | — | — | — | — | 12.9 | — | -52.8 | -135 | — | 35.0 |
| Profit before tax | 655 | 367 | 619 | 780 | 731 | 396 | 771 | 896 | 781 | 423 | 772 | 1,000 |
| Tax | 50.6 | 62.9 | 69.1 | 78.3 | 90.3 | 73.3 | 103 | 116 | 128 | 171 | 251 | 332 |
| Net profit | 604 | 304 | 550 | 702 | 641 | 322 | 668 | 779 | 653 | 251 | 521 | 667 |
| Profit to shareholders | 595 | 294 | 545 | 689 | 626 | 306 | 664 | 765 | 636 | 236 | 520 | 675 |
| EPS (₹) | 49.76 | 24.55 | 45.60 | 57.60 | 52.34 | 25.57 | 55.56 | 63.99 | 53.19 | 19.77 | 43.49 | 56.48 |
Profit & loss
Results for each year
8 financial years (April to March), consolidated, ₹ crore.
Sales, operating profit and net profit
Revenue · YoY (vs a year ago)
Net profit · YoY (vs a year ago)
| ₹ Cr | FY18 | FY19 | FY20 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6,431 | 7,357 | 8,344 | 10,634 | 11,599 | 12,668 | 12,965 | 14,712 |
| Other income | 96.0 | 87.7 | 104 | 163 | 216 | 311 | 494 | 583 |
| Total expenses | 5,601 | 6,490 | 7,189 | 8,938 | 10,408 | 10,834 | 10,931 | 12,250 |
| Employee cost | 1,192 | 1,362 | 1,505 | 1,963 | 2,131 | 2,201 | 2,454 | 2,837 |
| Operating profit | 1,028 | 1,115 | 1,473 | 2,038 | 1,506 | 2,124 | 2,512 | 2,830 |
| OPM % | 16.0% | 15.2% | 17.7% | 19.2% | 13.0% | 16.8% | 19.4% | 19.2% |
| Finance cost | 55.3 | 54.6 | 65.1 | 52.4 | 107 | 112 | 122 | 161 |
| Depreciation | 143 | 193 | 253 | 304 | 310 | 299 | 357 | 382 |
| Profit before tax | 926 | 955 | 1,260 | 1,844 | 1,305 | 2,023 | 2,527 | 2,871 |
| Tax | 288 | 181 | 110 | 164 | 298 | 212 | 311 | 518 |
| Tax rate % | 31.1% | 19.0% | 8.8% | 8.9% | 22.8% | 10.5% | 12.3% | 18.0% |
| Net profit | 638 | 774 | 1,149 | 1,680 | 1,007 | 1,811 | 2,215 | 2,351 |
| Profit to shareholders | 631 | 761 | 1,127 | 1,646 | 984 | 1,796 | 2,165 | 2,302 |
| Net margin % | 9.8% | 10.3% | 13.5% | 15.5% | 8.5% | 14.2% | 16.7% | 15.6% |
| EPS (₹) | 52.77 | 63.61 | 94.26 | 137.63 | 82.31 | 150.19 | 181.11 | 192.51 |
Balance sheet
Assets and debt
At each year end (and the latest half year), ₹ crore.
Equity, debt and assets
Shareholders' equity · YoY (vs a year ago)
| ₹ Cr | Mar 23 | Mar 24 | Mar 25 | Mar 26 | Sep 26 |
|---|---|---|---|---|---|
| Shareholders' equity | 9,045 | 10,312 | 11,985 | 13,820 | 14,865 |
| Long-term borrowings | 70.3 | 40.0 | 311 | 492 | 1,033 |
| Short-term borrowings | 1,326 | 1,174 | 752 | 1,131 | 830 |
| Total borrowings | 1,397 | 1,214 | 1,063 | 1,624 | 1,863 |
| Current liabilities | 3,707 | 3,995 | 3,959 | 4,783 | 4,709 |
| Fixed assets (PPE) | 2,065 | 2,161 | 2,064 | 2,695 | 3,154 |
| Inventories | 2,608 | 2,661 | 2,922 | 3,333 | 3,525 |
| Trade receivables | 2,132 | 2,253 | 2,466 | 2,979 | 3,370 |
| Cash & equivalents | 274 | 455 | 304 | 248 | 408 |
| Current assets | 8,606 | 10,412 | 10,811 | 12,211 | 13,066 |
| Total assets | 13,757 | 15,575 | 17,691 | 20,873 | 23,060 |
| Debt / equity | 0.15 | 0.12 | 0.09 | 0.12 | 0.13 |
Cash flow
Cash coming in and going out
For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.
Operating, investing and financing cash
Operations · YoY (vs a year ago)
| ₹ Cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 1,111 | 1,683 | 1,948 | 1,913 | 1,963 |
| Cash from investing | -1,435 | 113 | -1,009 | -1,299 | -1,667 |
| Cash from financing | 380 | -1,761 | -1,145 | -811 | -503 |
| Spent on fixed assets | -339 | -233 | -259 | -676 | -617 |
| Free cash flow | 772 | 1,450 | 1,689 | 1,237 | 1,346 |
| Net cash flow | 55.5 | 34.5 | -205 | -197 | -208 |
Shareholding
Who holds the shares
Promoter and public holding at each quarter end, as filed with NSE.
Holding over time
Latest (30 Jun 2026)
- Promoter & group
- 49.70%
- Public (FIIs, mutual funds, retail…)
- 50.30%
- Promoter change, last quarter
- -1.50 pts
Dividends & news
Latest dividends and announcements
Dividends & corporate actions
- Dividend - Rs 10 Per Share
- Interim Dividend - Rs 43 Per Share
- Dividend - Rs 8 Per Share
- Interim Dividend - Rs 37 Per Share
- Dividend - Rs 5 Per Share
- Interim Dividend - Rs 35 Per Share
- Dividend - Rs 10 Per Share
- Interim Dividend - Rs 15 Per Share & Special Dividend Rs 25 Per Share
Board meetings
- ALKEM LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2026 to inter-alia consider and approve the Unaudited F…
- the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026.
- ALKEM LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 14-Aug-2026 to inter-alia consider and approve the Unaudited F…
- Notice of meeting of the Board of Directors of Alkem Laboratories Limited ( the Company )
- the Yearly Audited Financial results of the Company for the period ended March 2026 and Dividend.
Filings with NSE
- Copy of Newspaper Publication
- Analysts/Institutional Investor Meet/Con. Call Updates
- Trading Window
- Investor Presentation
- Appointment
- Outcome of Board Meeting
- General Updates
Latest news
Alkem Laboratories Share PriceUpstox · 13 Nov, 1:30 pmIndia's Alkem Laboratories incorporates Saudi Arabia subsidiary to expand international presenceBioSpectrum Asia · 16 Nov, 1:49 pmAlkem Laboratories Ltd. Share Price Today - Alkem Laboratories Ltd. Stock Price Live NSE/BSECNBC TV18 · 13 Nov, 3:28 pmALKEM Outlook for the WeekEquitypandit · 8 Nov, 1:30 pmBuy Alkem Laboratories: target of Rs 6600: ICICI SecuritiesMoneycontrol.com · 16 Nov, 1:03 pmAlkem shares fall 3% after Q2 results; MOFSL retains Neutral ratingBusiness Standard · 13 Nov, 11:28 amAlkem Laboratories trading window opens November 16 after Q2 resultsscanx.trade · 12 Nov, 2:19 pmEarnings call transcript: Alkem Laboratories posts solid Q2 2027 sales, shares slip By Investing.comInvesting.com India · 12 Nov, 5:41 pmAbout
About Alkem Laboratories Limited
Alkem Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Specialising in generics and speciality pharmaceuticals, Alkem manufactures and markets pharmaceutical generics, formulations and nutraceuticals across India and global markets.
From Wikipedia (CC BY-SA 4.0).
Company details
- Company name
- Alkem Laboratories Limited
- NSE symbol
- ALKEM
- BSE scrip code
- 539523
- ISIN
- INE540L01014
- Listed on
- NSE, BSE
- Series
- EQ (normal equity)
- Listed on NSE since
- 23 Dec 2015
- Face value
- ₹2 per share
- Market lot
- 1 share
- Shares issued
- 11.96 crore
- Index
- NIFTY 500
- Sector (NSE)
- Healthcare
- Industry
- Pharmaceuticals: Major
- Managing director / CEO
- Sandeep Singh
- Chair
- Basudeo N. Singh
- Headquarters
- Mumbai
- Registered address
- Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai – 400013, Maharashtra, India
- Founded
- 1973
- Employees
- 23,386
- Financial year
- April to March
- Results basis
- Consolidated
- Website
- alkemlabs.com
Peers
Other Healthcare stocks
-
LAURUSLABSLaurus Labs ₹2,220.00 -8.42%
-
DIVISLABDivi's Laboratories ₹11,080.00 -3.16%
-
MAXHEALTHMax Healthcare Institute ₹1,009.90 +6.63%
-
APOLLOHOSPApollo Hospitals Enterprise ₹8,771.00 +2.87%
-
NATCOPHARMNATCO Pharma ₹828.65 +2.25%
-
AUROPHARMAAurobindo Pharma ₹1,794.00 -1.60%
-
PPLPHARMAPiramal Pharma ₹244.93 +0.16%
-
FORTISFortis Healthcare ₹803.20 +5.13%
Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.